Millions of people around the world struggle with mental health challenges, yet many treatments remain difficult to access or only partially effective. To address these challenges, Wellcome commissioned Technopolis to conduct a comprehensive study aimed at improving the mental health R&D ecosystem.

The study mapped out the complex landscape of mental health research and development, highlighting the unique paths that different treatments—such as pharmaceuticals, medical devices, and digital tools—must navigate from concept to market. It identified significant barriers, including high development costs, complex regulations and policy environment, and a perceived lack of market appeal, which deter developers and investors from pursuing new mental health treatments. Additionally, issues like participant recruitment for clinical trials and the stigma surrounding mental health further complicate progress.

A key insight from the study was the importance of involving people with lived experience in the development process. Their input ensures that new treatments are relevant and more likely to be adopted in real-world settings. The study also emphasised the need for increased funding, stronger collaboration among stakeholders, and advocacy for policies that foster innovation in mental health R&D. By addressing these challenges, the study aims to pave the way for more effective and accessible treatments for mental health conditions, offering a roadmap for future improvements in this critical area of healthcare.

You can also access the study online here.

Peter Varnai
Partner

Marisa Amato
Our colleague has moved on from Technopolis, and we wish them all the best in their future endeavours! Continue to explore our website to find out more about our work.